Baxter International Inc. (NYSE:BAX – Free Report) – Investment analysts at Zacks Research reduced their Q3 2026 EPS estimates for shares of Baxter International in a research report issued to clients and investors on Monday, September 28th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $0.51 for the quarter, down from their previous estimate of $0.53. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Baxter International’s current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Baxter International’s Q4 2026 earnings at $0.60 EPS, FY2026 earnings at $2.04 EPS, Q3 2027 earnings at $0.50 EPS, Q4 2027 earnings at $0.52 EPS, FY2027 earnings at $1.98 EPS and FY2028 earnings at $2.11 EPS.
Other equities analysts have also issued reports about the company. UBS Group raised their price target on Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a research report on Tuesday, July 28th. The Goldman Sachs Group increased their price objective on Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Weiss Ratings raised shares of Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Citigroup raised shares of Baxter International from a “sell” rating to a “neutral” rating and increased their price target for the company from $17.00 to $28.00 in a research report on Friday, July 31st. Finally, Wall Street Zen raised shares of Baxter International from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $22.45.
Baxter International Stock Up 0.0%
BAX opened at $23.50 on Wednesday. Baxter International has a 12 month low of $15.73 and a 12 month high of $30.00. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 1.39. The business’s 50-day moving average price is $25.22 and its 200-day moving average price is $21.20. The company has a market cap of $12.15 billion, a P/E ratio of -11.35, a P/E/G ratio of 3.55 and a beta of 0.60.
Baxter International (NYSE:BAX – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The business had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $2.80 billion. During the same period in the previous year, the firm posted $0.59 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS.
Baxter International Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Friday, August 28th will be given a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, August 28th. Baxter International’s dividend payout ratio (DPR) is currently -1.93%.
Institutional Investors Weigh In On Baxter International
A number of large investors have recently modified their holdings of the stock. Jones Financial Companies Lllp bought a new stake in Baxter International during the 2nd quarter valued at approximately $26,000. CYBER HORNET ETFs LLC grew its stake in Baxter International by 52.4% in the second quarter. CYBER HORNET ETFs LLC now owns 2,153 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 740 shares during the period. Community Bank N.A. bought a new position in Baxter International in the second quarter worth $46,000. Versant Capital Management Inc raised its holdings in Baxter International by 552.2% in the second quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 2,043 shares in the last quarter. Finally, EFG International AG purchased a new position in Baxter International during the second quarter valued at $67,000. Institutional investors own 90.19% of the company’s stock.
Key Baxter International News
Here are the key news stories impacting Baxter International this week:
- Positive Sentiment: Zacks Research modestly raised its Q2 2027 EPS forecast to $0.51 from $0.50, and a separate Zacks feature highlighted Baxter among medical stocks with potential earnings-surprise prospects. However, Zacks continues to rate the shares “Hold.” Zacks Research Issues Optimistic Estimate for BAX Earnings Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- Neutral Sentiment: Analyst coverage indicates a consensus price target of $22.45, while reports said Baxter shares were trading above that level. This may limit near-term upside unless estimates or sentiment improve. Baxter International Inc. Stock Has Consensus Target Price of $22.45 Baxter International Stock Trades Above Analyst Target
- Negative Sentiment: Zacks lowered its EPS forecasts for Q3 2026 to $0.51 from $0.53, Q4 2026 to $0.60 from $0.62, FY2026 to $2.04 from $2.06, FY2027 to $1.98 from $2.07, and FY2028 to $2.11 from $2.15. It also cut Q3 2027 to $0.50 from $0.53 and Q4 2027 to $0.52 from $0.59. The reductions suggest softer expected earnings growth and could weigh on BAX despite the unchanged “Hold” rating.
About Baxter International
Baxter International Inc is a global healthcare company that develops and markets products used in hospitals, outpatient facilities and other care settings. Its portfolio includes intravenous solutions and administration sets, infusion pumps, parenteral nutrition products, injectable medicines, surgical products and systems for medication preparation and delivery.
The company also provides products and technologies that support anesthesia, critical care, patient monitoring and other hospital workflows.
Featured Articles
- Five stocks we like better than Baxter International
- The Bull Case for Amprius Technologies Just Got Stronger
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.
